Expertise in
14
conditions

Francois Provot

CHRU De Lille
Lille, FR 
Expertise in
14
conditions
CHRU De Lille
Lille, FR 

Overview

Francois Provot practices practicing medicine in Lille, France.

Mr. Provot is highly rated in 14 conditions, according to our data. His clinical expertise encompasses Thrombocytopenia, D-Plus Hemolytic Uremic Syndrome, Hemolytic-Uremic Syndrome, D-Minus Hemolytic Uremic Syndrome, and Kidney Transplant.

He is actively involved in clinical research, co-authoring 108 peer reviewed articles and participating in 4 clinical trials.

Gender

Male

Locations

CHRU de Lille
Lille, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Phase 3b, Prospective, Open-label, Multicenter, Single Treatment Arm, Continuation Study of the Safety and Efficacy of TAK-755 (rADAMTS13, Also Known as BAX 930/SHP655) in the Prophylactic and On-demand Treatment of Subjects With Severe Congenital Thrombotic Thrombocytopenic Purpura (cTTP; Upshaw-Schulman Syndrome, or Hereditary Thrombotic Thrombocytopenic Purpura)
A Phase 3b, Prospective, Open-label, Multicenter, Single Treatment Arm, Continuation Study of the Safety and Efficacy of TAK-755 (rADAMTS13, Also Known as BAX 930/SHP655) in the Prophylactic and On-demand Treatment of Subjects With Severe Congenital Thrombotic Thrombocytopenic Purpura (cTTP; Upshaw-Schulman Syndrome, or Hereditary Thrombotic Thrombocytopenic Purpura)
Enrollment Status: Active_not_recruiting
Publish Date: April 02, 2026
Intervention Type: Biological
Study Drug: TAK-755
Study Phase: Phase 3
A Phase 3, Prospective, Randomized, Controlled, Open-label, Multicenter, 2 Period Crossover Study With a Single Arm Continuation Evaluating the Safety And Efficacy of BAX 930 (rADAMTS13) in the Prophylactic And On-demand Treatment of Subjects With Severe Congenital Thrombotic Thrombocytopenic Purpura (cTTP, Upshaw-Schulman Syndrome [USS], Hereditary Thrombotic Thrombocytopenic Purpura [hTTP])
A Phase 3, Prospective, Randomized, Controlled, Open-label, Multicenter, 2 Period Crossover Study With a Single Arm Continuation Evaluating the Safety And Efficacy of BAX 930 (rADAMTS13) in the Prophylactic And On-demand Treatment of Subjects With Severe Congenital Thrombotic Thrombocytopenic Purpura (cTTP, Upshaw-Schulman Syndrome [USS], Hereditary Thrombotic Thrombocytopenic Purpura [hTTP])
Enrollment Status: Completed
Publish Date: February 09, 2026
Intervention Type: Biological
Study Drug: BAX930
Study Phase: Phase 3
ALdosterone Antagonist Chronic HEModialysis Interventional Survival Trial (ALCHEMIST), Phase III b
ALdosterone Antagonist Chronic HEModialysis Interventional Survival Trial (ALCHEMIST), Phase III b
Enrollment Status: Completed
Publish Date: October 10, 2023
Intervention Type: Drug
Study Drug: Spironolactone
Study Phase: Phase 3
Multicentric, Prospective Open-label Study Assessing an Algorithm-based Strategy of Eculizumab Discontinuation in Children and Adults With Atypical Hemolytic Uremic Syndrome (aHUS)
Multicentric, Prospective Open-label Study Assessing an Algorithm-based Strategy of Eculizumab Discontinuation in Children and Adults With Atypical Hemolytic Uremic Syndrome (aHUS)
Enrollment Status: Completed
Publish Date: December 06, 2019
Intervention Type: Drug
Study Phase: Phase 4
View 3 Less Clinical Trials

108 Total Publications

Real-time, Multidisciplinary Approach of Women With Pregnancy-Associated Thrombotic Microangiopathy.
Real-time, Multidisciplinary Approach of Women With Pregnancy-Associated Thrombotic Microangiopathy.
Journal: Kidney international reports
Published: May 23, 2026

Frequently Asked Questions about Francois Provot

Is Francois Provot a top-rated expert for Thrombocytopenia?

MediFind is an objective health platform that identifies experts based on real-world data. Francois Provot is classified as an Elite expert for Thrombocytopenia, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Francois Provot participate in research or clinical trials?

Yes. Francois Provot has published 108 articles and abstracts on conditions like Thrombocytopenia. You can view a list of Francois Provot's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Provot's expertise for a condition
ConditionClose
View All 29 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile